RxSight (NASDAQ:RXST) Issues Quarterly Earnings Results

RxSight (NASDAQ:RXST) announced its quarterly earnings data on Tuesday. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.31) by ($0.08), Zacks reports. RxSight had a negative net margin of 36.80% and a negative return on equity of 17.35%. The firm had revenue of $24.59 million for the quarter, compared to analysts’ expectations of $27.19 million.

Here are the key takeaways from RxSight’s conference call:

• Third-quarter revenue fell 19% year over year to $24.6 million, while LAL procedure volume declined 11% to 23,128 units amid competitive pressure, seasonality, and internal restructuring disruption. Gross margin also decreased to 73.6%, partly due to higher inventory reserves.
• RxSight is nearly doubling its U.S. sales force and adding experienced commercial leaders to increase physician engagement, improve practice workflow integration, and drive utilization across its existing installed base. Management said high-performing practices demonstrate that stronger sales coverage and training can produce durable volume growth.
• Management expects fourth-quarter LAL sales to be roughly in line with the second quarter, implying mid- to high-single-digit sequential growth, but cautioned that competitive product trialing and restructuring-related disruption will continue through year-end. Formal 2026 guidance remains suspended, with 2027 guidance expected alongside fourth-quarter results.
• The Alcon collaboration passed its initial 120-day milestone, securing the $60 million upfront payment and allowing the companies to continue developing a partnership that management believes could expand postoperative adjustability across most of the premium IOL market.
• A comprehensive restructuring across manufacturing, corporate functions, and international operations is expected to reduce operating expenses in 2027 and beyond while preserving investment in the next-generation LAL pipeline and Alcon partnership. The company ended the quarter with $254.7 million in cash and short-term investments.

RxSight Price Performance

RXST opened at $4.59 on Wednesday. The firm has a market cap of $190.90 million, a PE ratio of -4.06 and a beta of 1.21. The stock has a 50-day moving average price of $5.33 and a 200-day moving average price of $6.34. RxSight has a 1 year low of $4.40 and a 1 year high of $13.22.

Analyst Ratings Changes

Several research analysts recently issued reports on RXST shares. UBS Group increased their price target on shares of RxSight from $5.50 to $6.30 and gave the stock a “neutral” rating in a research note on Thursday, August 6th. Wall Street Zen cut shares of RxSight from a “hold” rating to a “sell” rating in a report on Sunday, October 25th. Bank of America decreased their target price on shares of RxSight from $6.50 to $5.50 and set an “underperform” rating for the company in a research note on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (e+)” rating on shares of RxSight in a report on Tuesday, September 8th. Finally, Jefferies Financial Group dropped their price target on RxSight from $6.50 to $5.75 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Two investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $8.17.

Insider Activity

In other RxSight news, CFO Mark Wilterding sold 7,765 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total transaction of $54,044.40. Following the completion of the sale, the chief financial officer directly owned 25,049 shares in the company, valued at approximately $174,341.04. This trade represents a 23.66% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider M Kurtz sold 5,100 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $6.96, for a total transaction of $35,496.00. Following the sale, the insider owned 71,775 shares of the company’s stock, valued at approximately $499,554. This represents a 6.63% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,947 shares of company stock worth $117,951 over the last three months. 10.05% of the stock is currently owned by insiders.

About RxSight

RxSight, Inc is a medical technology company focused on improving visual outcomes for patients undergoing cataract surgery. The company develops and commercializes ophthalmic products that allow surgeons to customize a patient’s vision after surgery.

Its primary product is the RxSight Light Adjustable Lens, an intraocular lens implanted during cataract surgery. After implantation, the lens can be adjusted using ultraviolet light treatments delivered by the company’s Light Delivery Device, enabling physicians to refine the lens power based on the patient’s postoperative visual needs.